SRR975587
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.510
- E2F_TARGETS+0.490
- FATTY_ACID_METABOLISM+0.490
- XENOBIOTIC_METABOLISM+0.490
- MYC_TARGETS_V2+0.480
- PEROXISOME+0.400
- G2M_CHECKPOINT+0.380
- COAGULATION+0.330
- MYC_TARGETS_V1+0.320
- OXIDATIVE_PHOSPHORYLATION+0.280
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.450
- TNFA_SIGNALING_VIA_NFKB-0.440
- TGF_BETA_SIGNALING-0.420
- NOTCH_SIGNALING-0.390
- APICAL_SURFACE-0.380
- INTERFERON_ALPHA_RESPONSE-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- IL6_JAK_STAT3_SIGNALING-0.340
- INFLAMMATORY_RESPONSE-0.320
- P53_PATHWAY-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0040_T2_RNA | — | C | 0.867 |
| 2 | SRR975597 | — | — | 0.786 |
| 3 | X6b912c88.db40.4bde.8333.79829f05fade | — | cohortA4 | 0.773 |
| 4 | TCGA-37-5819-01A-01R-1635-07 | — | cohortA3 | 0.760 |
| 5 | TCGA-86-A4D0-01A-11R-A24H-07 | — | cohortA3 | 0.759 |
| 6 | SRR1313127 | — | B | 0.753 |
| 7 | TCGA-A7-A4SF-01A-11R-A266-07 | — | B | 0.752 |
| 8 | TCGA-4Z-AA87-01A-11R-A39I-07 | — | — | 0.752 |
| 9 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.750 |
| 10 | C3L-00415 | — | cohortSQ1 | 0.749 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.510 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.490 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| PEROXISOME | 0.400 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |